

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(formerly known as China Pharmaceutical Group Limited 中國製藥集團有限公司)

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

DISCLOSEABLE TRANSACTION DISPOSAL OF A WHOLLY-OWNED SUBSIDIARY

UPDATE OF THE STATUS AND CLARIFICATION

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 4 June 2013 (the “**Announcement**”) in respect of the disposal of CSPC Zhongrun Pharmaceutical (Inner Mongolia) Co., Ltd.* (“**Zhongrun (NMG)**”), a direct wholly-owned subsidiary of the Company. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

The Disposal was completed on 18 June 2013 pursuant to the terms of the Agreement as disclosed in the Announcement, with (i) the balance of the Consideration paid by the Purchaser to the Company on 17 June 2013; (ii) a bank guarantee in the amount of RMB800,000,000 issued to a designated subsidiary of the Company on 4 June 2013; and (iii) the industrial and commercial registration procedures relating to the Sale Interest completed on 18 June 2013.

Due to an inadvertent error, it was stated in the Announcement that Cenway was owned as to 43.97% by Zhongrun (NMG), 45.76% by a non-wholly owned subsidiary of the Company and 10.27% by an independent third party as at the date of the Agreement. The Company wishes to clarify that Cenway was in fact owned as to 89.73% by Zhongrun (NMG) and 10.27% by an independent third party as at the date of the Agreement, and accordingly, upon completion of the Disposal, Zhongrun (NMG) will cease to be a subsidiary of the Company and the Company will no longer have any interest

in Zhongrun (NMG), Zhongkang and Cenway. The above clarification does not affect the terms of the Agreement or have any adverse impact on the amount of expected gain to the Company upon completion of the Disposal.

By order of the Board of
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 17 July 2013

* *for identification purpose only*

As at the date of this announcement, the Board of the Company comprises Mr. Cai Dongchen, Mr. Feng Zhenying, Mr. Chak Kin Man, Mr. Pan Weidong, Mr. Zhao John Huan, Mr. Wang Shunlong, Mr. Wang Huaiyu, Mr. Lu Jianmin, Mr. Wang Zhenguo and Mr. Wang Jinxu as executive directors; Mr. Lee Ka Sze, Carmelo as non-executive director and Mr. Huo Zhenxing, Mr. Qi Moujia, Mr. Guo Shichang, Mr. Chan Siu Keung, Leonard, Mr. Wang Bo and Mr. Zhang Fawang as independent non-executive directors.